Tango Therapeutics

Tango Therapeutics' Mission and Vision

Founded in 2017, Tango Therapeutics aims to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. The company develops oncology medicines to expand treatment options for those living with cancer, focusing on diseases with high unmet need where patients share a common genetic context. Leveraging the principle of synthetic lethality, Tango Therapeutics is committed to addressing the broad unmet need in cancer treatment, ensuring that the right patients receive the most effective therapies.

Tango Therapeutics' Pipeline and Clinical Trials

Tango Therapeutics has a robust pipeline consisting of programs for genetically defined subsets of cancers with limited treatment options. The company currently has open and recruiting clinical trials for several key candidates, including TNG348, TNG260, TNG462, and TNG908. TNG908 is a synthetic lethal PRMT5 inhibitor in a Phase 1/2 trial targeting MTAP-deleted tumors. TNG462, a next-generation PRMT5 inhibitor, is also in a Phase 1/2 trial with enhanced potency and selectivity. Additionally, TNG260 is being evaluated in combination with pembrolizumab for STK11-mutant cancers, while TNG348 is in a dose-escalation trial assessing its efficacy as a single agent and in combination with olaparib.

Tango Therapeutics' CRISPR-based Target Discovery

Tango Therapeutics has built a state-of-the-art CRISPR-based functional genomics target discovery platform and a powerful bio-analytic pipeline. This high-throughput CRISPR-based functional genomics screening allows the company to identify synthetic lethal vulnerabilities in cancer cells, enabling the discovery and validation of novel therapeutic targets. By focusing on the genetic context of diseases, Tango Therapeutics ensures that its treatments are precisely tailored to target specific tumor types, thereby maximizing efficacy and minimizing off-target effects.

Tango Therapeutics' Strategic Collaborations

Tango Therapeutics has established a global strategic collaboration with Gilead Sciences, focusing on the discovery, development, and commercialization of targeted immune evasion therapies. This partnership enhances Tango's capabilities in developing next-generation oncology treatments. Despite this collaboration, Tango retains all rights to its three lead programs and targets identified outside the immune evasion space, ensuring the company maintains control over its key assets and strategic direction.

Tango Therapeutics' Lead Programs

Tango Therapeutics' lead programs include TNG908, TNG462, TNG260, and TNG348. TNG908 is a synthetic lethal PRMT5 inhibitor that selectively kills cancer cells with MTAP deletions. TNG462 is a next-generation PRMT5 inhibitor with enhanced potency and selectivity in MTAP-deleted xenograft models. TNG260 is a novel CoREST inhibitor aimed at reversing immune evasion in STK11 mutated cancers. Lastly, TNG348 is a synthetic lethal USP1 inhibitor targeting HRD+-mutant cells, including BRCA1 and BRCA2 mutations. These programs highlight Tango's innovative approach to developing targeted cancer therapies.